TOI Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Valuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 0.76
- P/S (TTM)
- 0.96
- EV/EBITDA
- 8.53
Profitability & growth
- ROE (TTM)
- -652.0%
- Operating margin
- -4.4%
- Revenue growth YoY
- 41.2%
- Dividend yield
- —
- Beta
- 0.41
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About Oncology Institute Inc
Company profileOncology Institute Inc (ticker: TOI) is a premier healthcare organization dedicated to transforming cancer care through its extensive network of specialized clinics and innovative treatment methodologies. The company leverages advanced technologies and personalized care strategies to enhance patient outcomes, while also prioritizing clinical trials and collaborations with leading research institutions. As the demand for advanced cancer therapies grows, TOI is strategically positioned to capitalize on this market trend, underpinned by a robust pipeline and a deep reservoir of oncology…
Classification
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 18000 STUDEBAKER ROAD, CERRITOS, CA
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
